SCHEMBL2963239

SCHEMBL2963239

N#Cc1ccc(NCCCO)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MERTK Q12866 1/20 0.52
ALDH1A1 P00352 2/20 0.43
SAE1 Q9UBE0 1/20 0.42
UBA2 Q9UBT2 1/20 0.42
IDO1 P14902 1/20 0.41
MMP2 P08253 1/20 0.41
CA2 P00918 2/20 0.40
CA12 O43570 1/20 0.40
CA3 P07451 1/20 0.40
CA6 P23280 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
MAPT P10636 3/20 0.40
LMNA P02545 2/20 0.40
TSHR P16473 1/20 0.40
HTT P42858 1/20 0.40
NLRP3 Q96P20 1/20 0.40
PRSS1 P07477 2/20 0.39
CA1 P00915 1/20 0.39
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8977551 0.95 MERTK (0.49) MERTKALDH1A1SAE1UBA2IDO1
SCHEMBL31475206 0.94 ALDH1A1 (0.50) MERTKALDH1A1SAE1UBA2IDO1
SCHEMBL11177848 0.93 ALDH1A1 (0.49) MERTKALDH1A1SAE1UBA2IDO1
SCHEMBL23961158 0.93 ALDH1A1 (0.49) MERTKALDH1A1SAE1UBA2IDO1
SCHEMBL3787398 0.90 ALDH1A1 (0.46) MERTKALDH1A1SAE1UBA2TSHR
SCHEMBL1063377 0.88 SAE1 (0.44) MERTKALDH1A1SAE1UBA2IDO1
SCHEMBL5516545 0.88 ALDH1A1 (0.44) ALDH1A1SAE1UBA2IDO1MMP2
SCHEMBL5712390 0.86 PRSS1 (0.46) ALDH1A1SAE1UBA2CA2MAPT
SCHEMBL5712397 0.86 PRSS1 (0.46) ALDH1A1SAE1UBA2CA2MAPT
SCHEMBL6418566 0.86 PRSS1 (0.46) ALDH1A1SAE1UBA2CA2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072637-A1 OXYGENATED HETEROCYCLIC LSD-1 INHIBITORS AND RELATED METHODS OF USE THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2025-04-03 WO disclosed
US-7772229-B2 Oxabispidine compounds useful in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2010-08-10 US disclosed
US-20090326221-A1 New oxabispidine compunds useful in the treatment of cardiac arrhythmias ASTRAZENECA AB, (SE) 2009-12-31 US disclosed
CN-101265262-A New oxabispidine compounds useful in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2008-09-17 CN disclosed
CN-100379743-C Oxabispidine compounds for the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2008-04-09 CN disclosed
US-7351821-B2 Oxabispidine compounds useful in the treatment of cardiac arrhythmias ASTRAZENECA AB (SE) 2008-04-01 US disclosed
US-20070197519-A1 New Process For The Preparation Of Oxabispidines ASTRAZENECA AB (SE) 2007-08-23 US disclosed
US-20070117799-A1 Oxabispidine compounds useful in the treatment of cardiac arrhythmias ASTRAZENECA AB, SODERTALJE, SWEDEN 2007-05-24 US disclosed
US-7217708-B2 Cardiovascular disorders ASTRAZENECA AB (SE) 2007-05-15 US disclosed
US-7169921-B2 Process for the preparation of oxabispidines ASTRAZENECA AB (SE) 2007-01-30 US disclosed
EP-1235831-A2 NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-09-04 EP disclosed
WO-2002060902-A1 3,7-DIAZABICYCLO[3.3.0]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-08-08 WO disclosed
WO-2002032902-A1 3,8-DIAZABICYCLO[3.2.1]OCTANES AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-04-25 WO disclosed
WO-2002028863-A1 NEW OXABISPIDINE COMPOUND USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2002-04-11 WO disclosed
EP-1192154-A1 BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-04-03 EP disclosed
EP-1192157-A1 BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS AstraZeneca AB (SE) 2002-04-03 EP disclosed
WO-2001047893-A1 NEW AZABICYCLOOCTANE DERIVATIVES USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2001-07-05 WO disclosed
WO-2001028992-A2 NEW OXABISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2001-04-26 WO disclosed
WO-2000076999-A1 NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2000-12-21 WO disclosed
WO-2000077000-A1 NEW BISPIDINE COMPOUNDS USEFUL IN THE TREATMENT OF CARDIAC ARRHYTHMIAS ASTRAZENECA AB (SE) 2000-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326221-A1 New oxabispidine compunds useful in the treatment of cardiac arrhythmias KCNH1, CACNA1E, SCN1B MERTK 3214/4885ALDH1A1 557/4885SAE1 3180/4885
US-20070117799-A1 Oxabispidine compounds useful in the treatment of cardiac arrhythmias KCNH1, RYR1, CACNA1E MERTK 2895/4885ALDH1A1 534/4885SAE1 3898/4885
US-20070197519-A1 New Process For The Preparation Of Oxabispidines TST, IDH3B, INTS6 MERTK 2882/4885ALDH1A1 47/4885SAE1 3333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.